Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Monforte, Antonella D'Arminio ^a   Cozzi Lepri, Alessandro ^b   Ceccherini Silberstein, Francesca ^c   De Luca, Andrea ^d   Caputo, Sergio Lo ^e   Castagna, Antonella ^f   Mussini, Cristina ^g   Cingolani, Antonella ^h   Tavelli, Alessandro ⁱ   Shanyinde, Milensu ^b   Gori, Andrea ^j   Girardi, Enrico ^k   Andreoni, Massimo ^c   Antinori, Andrea ^k   Puoti, Massimo ^l  

^a UNIVERSITY OF MILAN   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e POLICLINICO   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ ICONA Foundation   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

^k NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^l OSPEDALE NIGUARDA CA GRANDA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RITONAVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PREDICTION; REIMBURSEMENT; SUSTAINED VIROLOGICAL RESPONSE; COMORBIDITY; DISEASE MANAGEMENT; GENETICS; GENOTYPE; HEALTH CARE DELIVERY; HEPACIVIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TRANSMISSION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; COMORBIDITY; DISEASE MANAGEMENT; FEMALE; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85019849312     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0177402     Document Type: Article

References (25)

1. 1. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2 with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361:580-93. https://doi.org/10.1056/NEJMoa0808010 PMID: 19625712
2. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014; 147(1):132-42 e4. https://doi.org/10.1053/j.gastro.2014.03.051 PMID: 24704719
3. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013; 13(7):597-605. https://doi.org/10.1016/S1473-3099(13)70149-X PMID: 23768747
4. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med. 2013; 368(20):1878-1887 https://doi.org/10.1056/NEJMoa1214853 PMID: 23607594
5. Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, nonrandomised, phase 3 study. Lancet. 2015; 385(9973):1098-106. https://doi.org/10.1016/S0140-6736 (14)62483-1 PMID: 25659285
6. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373:714-25. https://doi.org/10.1056/NEJMoa1503153 PMID: 26196502
7. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373(8):705-13. https://doi.org/10.1056/NEJMoa1501315 PMID: 26196665
8. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir,paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 313(12):1223-31. https://doi.org/10.1001/jama.2015.1328 PMID: 25706092
9. Ward J and Mermin JH. Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs. N Engl J Med. 2015; 373(27):2678-2680 https://doi.org/10.1056/NEJMe1513245 PMID: 26575359
10. European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2015. J Hepatol. 2015; 63(1):199-236. https://doi.org/10.1016/j.jhep.2015.03.025 PMID: 25911336
11. AASLD/IDSA HCV Guidance Panel. AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus. Hepatology. 2015; 62(3): 932-954. https://doi.org/10.1002/hep.27950 PMID: 26111063
12. Piroth L, Rabaud C, Rey D, Schmit J, Chirouze C, Beck-Wirth G, et al. Hepatitis C: the path towards effective universal therapy. The Lancet. 2016; 388(10049):1051-1052.
13. AIFA Guidelines. Available from: http://www.agenziafarmaco.gov.it/it/content/aggiornamento-epatite-c.
14. Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E, et al. Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. PLoS One. 2015; 10(10).
15. Cope R, Pickering A, Glowa T, Faulds S, Veldkamp P, Prasad R. Majority of HIV/HCV patients need to switch antiretroviral therapy to accommodate direct acting antivirals. AIDS Patient Care and STDS. 2015; 29(7):379-383. https://doi.org/10.1089/apc.2015.0004 PMID: 26066094
16. EACS. HIV Guideline October 2016 8.1. 2016; (October). Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
17. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Philips AN, et al: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral nave patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Nave Patient. AIDS. 2000; 14(5):499-507. PMID: 10780712
18. Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA et al: Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med. 2014 Jan; 15(1):30-9. https://doi.org/10.1111/hiv.12082 PMID: 24007567
19. Boerekamps A, Newsum A, Smit C, Reiss P. Unrestricted DAA access in the Netherlands: rapid therapy uptake in HIV+HCV+ patients. CROI 2017; Seattle February 13-16 Abstract 136.
20. Boerekamps A, van den Berk G, Lauw F, Leyten E, Arends J, Kasteren M et al. Substantial decline in acute HCV infections among Dutch HIV+ MSM after DAA roll-out. CROI 2017; Seattle February 13-16 Abstract 137LB.
21. Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferrire V et al. How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. Clin Infect Dis. 2016; 62(7):919-26. https://doi.org/10.1093/cid/civ1222 PMID: 26743093
22. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015; 149(3):649-59. https://doi.org/10.1053/j.gastro.2015.05.010 PMID: 25985734
23. Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015; 62(3):715-25. https://doi.org/10.1002/hep.27922 PMID: 26033798
24. Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, et al: All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus±coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13±HEPAVIH Cohort. Clin Infect Dis. 2016; 63(6):763-70 https://doi.org/10.1093/cid/ciw379 PMID: 27317796
25. Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J: Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus±Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens. Clin Infect Dis. 2015; 61(6): 974-977. https://doi.org/10.1093/cid/civ419 PMID: 26021996